Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeraj Narula

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
BMJ Open Gastroenterology|February 15, 2022
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisEdouard Louis, Kristine Paridaens, Sameer Al Awadhi, et al.
Intestinal Research|April 15, 2022
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisJae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, et al.
Scandinavian Journal of Gastroenterology|December 21, 2021
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitisAxel U Dignass, Kristine Paridaens, Sameer Al Awadhi, et al.
Journal of Crohn'S & Colitis|March 9, 2026
Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel DiseaseAxel Dignass, Neeraj Narula, Krishan Pratap, et al.
The American Journal of Gastroenterology|December 29, 2022
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort StudyChristopher Ma, Remo Panaccione, Yasi Xiao, et al.
The American Journal of Gastroenterology|November 12, 2024
Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's DiseaseDina Kao, Karen Wong, Humberto Jijon, et al.
The American Journal of Gastroenterology|May 9, 2020
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule InhibitorsParambir S Dulai, Robert Battat, Maria Barsky, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
The American Journal of Gastroenterology|June 5, 2025
Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian StudyVirginia Solitano, Ropo Ebenezer Ogunsakin, Yuhong Yuan, et al.
Journal of Crohn'S & Colitis|February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential SolutionsMathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
BMJ Open Gastroenterology|February 15, 2022
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisEdouard Louis, Kristine Paridaens, Sameer Al Awadhi, et al.
Intestinal Research|April 15, 2022
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisJae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, et al.
Scandinavian Journal of Gastroenterology|December 21, 2021
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitisAxel U Dignass, Kristine Paridaens, Sameer Al Awadhi, et al.
Journal of Crohn'S & Colitis|March 9, 2026
Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel DiseaseAxel Dignass, Neeraj Narula, Krishan Pratap, et al.
The American Journal of Gastroenterology|December 29, 2022
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort StudyChristopher Ma, Remo Panaccione, Yasi Xiao, et al.
The American Journal of Gastroenterology|November 12, 2024
Preliminary Results From a Multicenter, Randomized Trial Using Fecal Microbiota Transplantation to Induce Remission in Patients With Mild-to-Moderate Crohn's DiseaseDina Kao, Karen Wong, Humberto Jijon, et al.
The American Journal of Gastroenterology|May 9, 2020
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule InhibitorsParambir S Dulai, Robert Battat, Maria Barsky, et al.
Journal of Crohn'S & Colitis|November 9, 2025
Placebo rates in randomized clinical trials of ulcerative colitis: an individual patient data meta-analysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
The American Journal of Gastroenterology|June 5, 2025
Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian StudyVirginia Solitano, Ropo Ebenezer Ogunsakin, Yuhong Yuan, et al.
Journal of Crohn'S & Colitis|February 4, 2023
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential SolutionsMathieu Uzzan, Yoram Bouhnik, Maria Abreu, et al.
Pageof 21